Atlas Trials

Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma

Clinical trial NCT03214250 · COMPLETED

Trial details

NCT number
NCT03214250
Sponsor
Parker Institute for Cancer Immunotherapy
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Metastatic Pancreatic Adenocarcinoma
Start date
2017-07-21
Primary completion
2021-02-11
Enrollment
129

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.